The U.S. Department of Justice has reclassified cannabis from a Schedule I to a Schedule III drug, aligning it with substances like Tylenol with codeine. Acting Attorney General Todd Blanche announced the change on Thursday, which applies to FDA-approved and state-licensed medical marijuana products. The move follows President Donald Trump's directive last year to expand access to medical treatment options. Marijuana remains illegal at the federal level, but the reclassification lowers regulatory barriers for research and could ease tax and banking restrictions for the cannabis industry.
Immediate Action & Core Facts
The reclassification shifts cannabis from Schedule I (high potential for abuse, no medical use) to Schedule III (recognized medical applications, lower regulatory restrictions). The change takes effect 30 days after publication in the Federal Register, though legal challenges are expected. A hearing in June will consider broader reclassification of all marijuana.
Deeper Dive & Context
Policy Implications
The reclassification allows for expanded research into cannabis's safety and efficacy, potentially improving patient care and medical decision-making. It also exempts cannabis companies from IRS Code Section 280E, enabling standard business deductions and improving banking access.
Political and Legal Context
While most U.S. states have legalized medical or recreational marijuana, federal prohibition remains. The move signals a growing willingness in Washington to reconsider cannabis policy, though it does not legalize recreational use nationwide. Critics may argue the change does not go far enough, while supporters highlight its potential to advance medical research.
Economic and Industry Impact
The financial implications are significant, as the reclassification could open doors for banking access and tax relief for cannabis businesses. However, the federal ban on marijuana sales persists, limiting the immediate economic benefits.